News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer
Praveen Kumar Marimuthu/X
May 1, 2025, 09:14

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an article by Rebecca Kristeleit, et al. on X:

“Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer.

  • 12-wk PFS: 42%.
  • ORR: 25%.
  • Median DOR: 13.1 mo.
  • Median OS: 14.8 mo.”

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: Jama Network

Authors: Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsel, Rowan E. Miller, et al.

You can Read the Full Article on Journal of JAMA NETWORK.

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

More posts featuring Praveen Kumar Marimuthu.

Advanced Clear Cell Gynecological Cancer Andrew Clamp C. Simon Herrington cancer Charlie Gourley Christian Medical College and Hospital clinical trial fight against cancer Global fight against cancer Gynecological Cancer JAMA Network Laura Farrelly Laura Hughes Lesley Sage Marcia Hall MedOnc Michael-John Devlin Nicholas Counsel OncoDaily Oncology pembrolizumab Praveen Kumar Marimuthu Priya Narayanan Rachel Nirsimloo Rebecca Kristeleit René Roux Rowan E. Miller Rupali Arora Valentinos Kounnis
Special Coverage
Blog
May 20, 2025, 17:22
The Lancet Group's Editorial Team Will Be on the Ground at ASCO 2025
Blog
May 20, 2025, 17:11
Pam Traxel: One in Ten Cancer Survivors Rely on Medicaid - Cuts Have Consequences
Blog
May 20, 2025, 16:58
Elvina Majiwa and Murallitharan Munisamy Have Won The World No Tobacco Day Award - UICC
Blog
May 20, 2025, 16:56
PER Tumor Board: Applying Recent Advances to Transform the Treatment Paradigm in SCLC
Blog
May 20, 2025, 16:46
Shahrin Ahmed: Specific Pre-surgery Medication Improves Survival Rates in Hereditary Breast Cancer Cases
Blog
May 20, 2025, 16:43
Ahmed Magdy Rabea: Pleased to Give a Multiple Myeloma Awareness Session to the Pfizer Egypt Team
Blog
May 20, 2025, 16:37
Sachin Jain: The Greatest Impact of AI Will Come from Improving Care and Service
Blog
May 20, 2025, 16:27
It Is Time to Invest in Cancer Research - Stand Up To Cancer
Insight
May 20, 2025, 15:50
Oliver Bogler Announced the Launch of the NanCI AI Webapp for Scientific Literature and Networking
Blog
May 20, 2025, 15:37
Fumiko Ladd Chino: Even with Superlative Healthcare You Can Still End Up with Stage 4 Cancer
Blog
May 20, 2025, 15:20
Save the date for the 7th CCI4EU Online Course - "Early Cancer Detection, Screening, and Prevention"
Insight
May 20, 2025, 15:05
New JCO Oncology Practice Piece on Debunking Myths of Hope in Cancer Care